Existing methods for detecting and diagnosing COVID-19 are either expensive and complex or inaccurate.

Danaher reported on Thursday a 12 percent year-over-year increase in total revenues.

On April 19, Maccura Biotechnology Co., Ltd. released its 2021 annual financial report. The company achieved CNY 3.981 billion revenue in 2021, a year-on-year increase of 7.47%; net profit attributable to shareholders of listed companies was CNY 957 million, a year-on-year increase of 20.49%.

Abbott announced before the market opened on Wednesday that its first quarter Diagnostics business revenues grew 32 percent year over year.

With the help of single-cell sequencing, a team from Boston Children's Hospital, the Broad Institute, Harvard Medical School, and elsewhere has found evidence for enhanced somatic mutation in brain cells from individuals with Alzheimer's disease.

A point-of-care COVID-19 test developed by researchers at the University of Illinois Urbana-Champaign can now detect and differentiate the alpha variant of the SARS-CoV-2 virus from earlier strains in saliva samples.

Diagnostics instrument and reagent developer MicroGem announced on Tuesday that it has obtained Emergency Use Authorization from the US Food and Drug Administration for a rapid point-of-care PCR instrument and COVID test.

On April 19, Mindary (300760.SZ) released its 2021 annual report, showing that in 2021 the company achieved revenue of CNY 25.270 billion, up 20.18%, achieved net profit attributable to the mother company of CNY 8.002 billion, up 20.19%.

In 2021, Gongdong Medical achieved operating income of CNY 1.194 billion, a year-on-year increase of 43.95%; net profit attributable to the parent company of CNY 311 million, a year-on-year increase of 37.68%.

Thermo Fisher Scientific has launched its first GMP-manufactured Cas9 protein for clinical genome editing research.

Chinese diagnostics firm Amoy Diagnostics on Monday announced that it has entered into a collaboration agreement with AstraZeneca to develop and commercialize AmoyDx assays that may cover any type of indication or biomarker for companion diagnostic use with AstraZeneca medicines.

On April 15, Wuhan Easy Diagnosis Biomedicine, Shenzhen YHLO Biotech and Acrobiosystemsreleased its first quarter results forecast for 2022

Eurobio Scientific said on Thursday that its molecular SARS-CoV-2 test for detecting viral variants has received CE marking.

The US Food and Drug Administration this week granted Emergency Use Authorization for the Cleveland Clinic's SelfCheck Cobas SARS-CoV-2 + Flu Assay.

Shanghai Rigen Biotech Co., Ltd. (hereinafter referred to as "Rigen") recently completed a new round of financing of nearly 100 million CNY.